Ironwood Pharmaceuticals Inc (IRWD) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Ironwood Pharmaceuticals inc   (NASDAQ: IRWD)


Ironwood Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Ironwood Pharmaceuticals Inc's ROI in the second quarter of 2026?
Ironwood Pharmaceuticals inc achieved a return on average invested assets (ROI) of 74.67 % in its second quarter of 2026, this is above IRWD's average return on investment of -32.25%.
Ironwood Pharmaceuticals Inc invested over the 12 months ending in its second quarter of 2026 $174 million

ROI fell compared to the first quarter of 2026, despite the net income growth of 25.8% from the first quarter of 2026.

Within the Healthcare sector 16 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 54 to 56.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -22.45 % -53.64 % -40.64 % -17.41 % 13.28 %
Y / Y Net Income Change TTM - - 376.34 % 924.73 % -
Investment (TTM) in Millions 252 168 155 121 77
Return On Investment (TTM) 74.67 % 78.56 % 15.95 % 15.63 % -3.52 %
IRWD's Overall Ranking # 56 # 54 # 430 # 320 # 2126
Seq. Investment Change TTM 33.72 % -13.65 % -17.52 % -18.58 % -20.06 %
Seq. Net Income Change TTM 27.1 % 325.43 % -15.87 % - -
Net Income (TTM) in Millions 130 102 24 29 -8




Return On Investment IRWD's Ranking
Within: No.
Industry # 7
Sector # 17
Overall # 56

Return On Investment Statistics
High Average Low
83.59 %
-32.25 %
-541.18 %
(Jun 30 2021)   (Mar 31 2024)







Financial Statements
Ironwood Pharmaceuticals Inc's II. Quarter Investments $ 252 Millions IRWD's Balance sheet
Ironwood Pharmaceuticals Inc's II. Quarter Income $ 51 Millions Quarterly IRWD's Income Statement
IRWD's Income by Division See IRWD's Income by Division


IRWD Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 123 283 152 1,049 1,414
Y / Y Investment Growth -56.43 % 85.94 % -85.5 % -25.85 % 179.06 %
Net Income in Millions 24 1 -1,032 175 528
Y / Y Net Income Growth 2629.2 % - - -66.87 % 397.71 %
Annual Return On Investment 19.5 % 0.31 % -678.59 % 16.69 % 37.37 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 19.5 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IRWD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IRWD's Competitors
Subscribers only: Roi for Ironwood Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for IRWD's Customers

Other Ratios
IRWD's Roa IRWD's Inventory Turnover Ratio IRWD's Growth Rates IRWD's Dividend Statistics
IRWD's Profitability Ratios IRWD's Asset Turnover Ratio IRWD's Dividend Growth
IRWD's Roe IRWD's Valuation Ratios IRWD's Financial Strength Ratios IRWD's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Omeros Corporation  198.34 %
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Arbutus Biopharma Corp  99.18 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %


Date modified: 2026-09-26T07:14:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.